After nebulizer flop, Verona touts interim PhII results on another version of its lead COPD drug

The London-based respiratory drug developer is reporting that interim results from the first part of its Phase II trial — showing that its dry powder inhaler formulation of ensifentrine helped patients improve lung function — look promising enough to go ahead with part 2.